Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma
Cancer Medicine · 2025
DOI: 10.1002/cam4.71361 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xiang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Renal Insufficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1.3.5 Project for High Altitude Medicine, Postdoctor Research Fund of West China Hospital, Sichan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Previous studies mainly focused on renal impairment (RI) at multiple myeloma (MM) diagnosis, with few investigating new‐onset RI post‐MM diagnosis. This study aims to indicate the incidence, clinical characteristics and predictive value of new‐onset RI in MM patients.
Methods
We conducted a multicenter, retrospective cohort study including 1953 newly diagnosed MM patients from West China Hospital from July 1, 2008, to February 30, 2024 and the international MMRF‐CoMMpass database. Among them, 1770 patients received novel therapeutic agents including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) as first‐line therapy. RI was defined as serum creatinine higher than 2 mg/dL or impaired creatinine clearance (< 40 mL/min/1.73m 2 ). The association between new‐onset RI and mortality risk was investigated by Kaplan–Meier analysis and Cox proportional hazard models.
Results
Of the cohort, 16.6% developed new‐onset RI, with the majority (67.1%) occurring within 2 years post‐MM diagnosis. The median overall survival (OS) was significantly shorter in new‐onset RI than in those without RI (68 vs. 122 months, p < 0.001). New‐onset RI was an independent risk factor for mortality (HR 1.55, 95% CI 1.28–1.88, p < 0.001), and earlier onset of RI was associated with a higher mortality risk. Moreover, patients with recovery of renal function had prolonged OS compared to those without recovery (95 vs. 64.8 months, p = 0.01). Older age, higher stage of the international stage system (ISS) and RI at diagnosis seemed to be risk factors for new‐onset RI, while first‐line therapy with PIs and IMiDs combinations was associated with a lower risk of RI development (HR 0.69, 95% CI 0.51–0.94, p = 0.017).
Conclusions
In conclusion, the incidence of new‐onset RI is high in MM, and is a significant risk factor for mortality, posing a substantial threat to MM patients. Early identification of high‐risk patients for new‐onset RI and prompt preventive strategies is critical for improving MM prognosis. Trial Registration This study was registered by the Chinese Clinical Trial Registry (ChiCTR2400081476, https://www.chictr.org.cn )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.
- State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Yuhuan Zheng, Wenjiao Tang, Ting Niu
Förderung
- 1.3.5 Project for High Altitude Medicine
- Postdoctor Research Fund of West China Hospital, Sichan University
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Liu, X., Hu, Q., Zheng, Y., Tang, W., & Niu, T. (2025). Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma. Cancer Medicine. https://doi.org/10.1002/cam4.71361
Vancouver
Liu X, Hu Q, Zheng Y, Tang W, Niu T. Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma. Cancer Medicine. 2025. doi:10.1002/cam4.71361
BibTeX
@article{Liu2025,
author = {Liu, Xiang and Hu, Qian and Zheng, Yuhuan and Tang, Wenjiao and Niu, Ting},
title = {Incidence, Clinical Features, and Prognostic Value of New‐Onset Renal Impairment in Multiple Myeloma},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71361}
}
EUVIMED